
Bionano Genomics (BNGO) Stock Forecast & Price Target
Bionano Genomics (BNGO) Analyst Ratings
Bulls say
Bionano Genomics has demonstrated a solid upward trajectory in sales, achieving a 17% increase in nanochannel array flowcell sales in 2Q25 compared to the prior year, alongside a 7% increase in 3Q25. The company reported an 11% year-over-year increase in combined revenue from consumables, software, and other sources in 2Q25, with consumables and software revenues increasing by 16%. Furthermore, expectations for new optical genome mapping (OGM) installations have improved for FY2025, with projected installations rising to 20-25, up from the previous estimate of 15-20, indicating strong demand and potential for future growth in new and existing markets.
Bears say
Bionano Genomics faces several significant risks that contribute to a negative outlook on its stock, including potential lower-than-expected market uptake of its products and reduced utilization of its installed systems. Additionally, the company may struggle to secure necessary capital to fund operations, which raises concerns about financial sustainability and could result in dilution for existing shareholders. Given the projected sales per share and conservative valuation metrics, the financial outlook appears bleak amid these operational challenges.
This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.
Bionano Genomics (BNGO) Analyst Forecast & Price Prediction
Start investing in Bionano Genomics (BNGO)
Order type
Buy in
Order amount
Est. shares
0 shares